These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28554223)

  • 1. Outpatient management of severe ovarian hyperstimulation syndrome: a systematic review and a review of existing guidelines.
    Gebril A; Hamoda H; Mathur R
    Hum Fertil (Camb); 2018 Jun; 21(2):98-105. PubMed ID: 28554223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Tarlatzi TB; Tarlatzis BC; Lainas TG
    Reprod Biol Endocrinol; 2012 Aug; 10():69. PubMed ID: 22938051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention and management of ovarian hyperstimulation syndrome.
    Chen CD; Chen SU; Yang YS
    Best Pract Res Clin Obstet Gynaecol; 2012 Dec; 26(6):817-27. PubMed ID: 22647872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis.
    Smith LP; Hacker MR; Alper MM
    Fertil Steril; 2009 Dec; 92(6):1953-9. PubMed ID: 18976762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist.
    Lainas TG; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas GT; Kolibianakis EM
    Reprod Biomed Online; 2007 Oct; 15(4):408-12. PubMed ID: 17908403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An ounce of prevention: outpatient management of the ovarian hyperstimulation syndrome.
    Fluker MR; Copeland JE; Yuzpe AA
    Fertil Steril; 2000 Apr; 73(4):821-4. PubMed ID: 10731547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol.
    Lainas TG; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas GT; Iliadis GS; Kolibianakis EM
    Reprod Biomed Online; 2009 Jan; 18(1):15-20. PubMed ID: 19146764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of ovarian hyperstimulation syndrome using gonadotropin releasing hormone antagonist: a pilot study.
    Hosseini MA; Mahdavi A; Aleyasin A; Safdarian L; Bahmaee F
    Gynecol Endocrinol; 2012 Nov; 28(11):853-5. PubMed ID: 22697477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High doses of GnRH antagonists are efficient in the management of severe ovarian hyperstimulation syndrome.
    Bonilla-Musoles FM; Raga F; Castillo JC; Sanz M; Dolz M; Osborne N
    Clin Exp Obstet Gynecol; 2009; 36(2):78-81. PubMed ID: 19688946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian hyperstimulation syndrome prevention strategies: use of gonadotropin-releasing hormone antagonists.
    Griesinger G
    Semin Reprod Med; 2010 Nov; 28(6):493-9. PubMed ID: 21082508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous abdominal paracentesis for management of late type severe ovarian hyperstimulation syndrome.
    Chan CC; Yin CS; Lan SC; Chen IC; Wu GJ
    J Chin Med Assoc; 2004 Apr; 67(4):197-9. PubMed ID: 15244020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    BJOG; 2014 Jun; 121(7):848-55. PubMed ID: 24621101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: "tap early and often" versus hospitalization.
    Csokmay JM; Yauger BJ; Henne MB; Armstrong AY; Queenan JT; Segars JH
    Fertil Steril; 2010 Jan; 93(1):167-73. PubMed ID: 18990389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outpatient paracentesis for the management of ovarian hyperstimulation syndrome: study protocol for the STOP-OHSS randomised controlled trial.
    White DA; Pye C; Ridsdale K; Dimairo M; Mooney C; Wright J; Young TA; Cheong YC; Drakeley A; Mathur R; O'Cathain A; Desoysa L; Sizer A; Lumley E; Chatters R; Metwally M
    BMJ Open; 2024 Jan; 14(1):e076434. PubMed ID: 38262643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
    Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Removal of ascites up to 7.5 liters on one occasion and 45 liters in total may be safe in patients with severe ovarian hyperstimulation syndrome.
    Ozgun MT; Batukan C; Oner G; Uludag S; Aygen EM; Sahin Y
    Gynecol Endocrinol; 2008 Nov; 24(11):656-8. PubMed ID: 19031224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
    Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
    Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.